RPRX · XBRL financial data

Royalty Pharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RPRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	2,122	2,289	2,237	2,355	2,264	2,378
Research and development	26	200	177	52	2	452
General and administrative	182	183	227	250	237	573
Operating income (loss)	1,595	1,431	307	1,492	1,292	1,560
Interest expense	157	166	188	187	226	308
Other income (expense)	(33)	(6)	(15)	(22)	(2)	(14)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	975	620	43	1,135	859	771
Earnings per share, basic USD per share	1.32	1.49	0.10	2.54	1.92	1.79
Earnings per share, diluted USD per share	1.32	1.49	0.10	2.53	1.91	1.78
Weighted average shares, basic millions of shares	375	415	438	448	448	430
Weighted average shares, diluted millions of shares	375	415	438	603	594	564

Fiscal years (RPRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,009	1,541	1,711	477	929	619
Marketable securities	70	66	1	18	58	19
Marketable securities, non-current	144	204	226	437	694	419
Total current assets	2,697	2,878	2,555	1,274	1,802	1,528
Goodwill	—	—	—	—	0	925
Total assets	16,020	17,516	16,813	16,382	18,223	19,621
Current portion of long-term debt	0	0	998	0	998	380
Total current liabilities	308	171	1,167	161	1,254	636
Long-term debt	5,817	7,096	6,119	6,135	6,615	8,571
Total liabilities	6,124	7,267	7,288	6,298	7,880	9,906
Retained earnings	1,921	2,255	1,965	2,518	2,846	2,356
Total liabilities and equity	16,020	17,516	16,813	16,382	18,223	19,621

Fiscal years (RPRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	975	620	43	1,135	859	771
Stock-based compensation	5	2	2	2	2	290
Net cash from operating activities	2,035	2,018	2,144	2,988	2,769	2,490
Net cash from investing activities	(2,759)	(1,870)	(1,029)	(2,073)	(2,678)	(1,614)
Share repurchases	0	0	0	305	230	1,227
Proceeds from long-term debt	11,891	1,273	0	—	—	—
Repayments of long-term debt	11,116	0	0	—	—	—
Net cash from financing activities	1,487	385	(945)	(2,149)	361	(1,186)
Net change in cash	762	532	170	(1,234)	452	(310)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Royalty Pharma	514	690	686*	not reported	—	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,781	1,890	509*	1.5B	—	Q3 FY26 10-QSep 30, 2026
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
United Therapeutics	1,189	833	307*	42.6M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 6:38 AM ET. The filing on SEC.gov is the record.